Physician profile
John A Frith
NPI 1679834097
$32,991.70
in general payments reported to CMS, 2019-2025
37 companies · $1,421 in 2025
The $1,421 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,609 · 2020: $5,409 · 2021: $6,741 · 2022: $5,706 · 2023: $10K · 2024: $1,608 · 2025: $1,421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,935 · Food and Beverage: $5,327 · Travel and Lodging: $1,227 · Consulting Fee: $36.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,935.00 |
| Food and Beverage | $5,327.12 |
| Travel and Lodging | $1,227.17 |
| Consulting Fee | $36.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $22,696.53 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $2,480.01 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,257.85 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $993.64 | 2020-2025 | Hyqvia, Takhzyro |
| Genzyme Corporation | $844.50 | 2019-2025 | |
| Csl Behring | $669.59 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Alk-Abello, INC | $462.19 | 2019-2025 | Timothy, Standardized, Histamine Positive, Alternaria Tenuis |
| Pfizer INC. | $362.55 | 2019-2024 | |
| Kaleo, INC. | $356.40 | 2020-2024 | Auvi-Q |
| Genentech USA, INC. | $323.78 | 2019-2024 | Xolair |
| Teva Pharmaceuticals USA, INC. | $319.61 | 2019-2022 | |
| Pharming Healthcare, INC. | $289.99 | 2022-2025 | Ruconest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.03 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $272.40 | 2019-2025 | |
| Octapharma USA, INC. | $167.42 | 2023-2025 | Panzyga, Cutaquig |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $134.22 | 2021-2025 | Orladeyo |
| Aimmune Therapeutics, INC. | $103.65 | 2021-2023 | |
| Grifols USA, LLC | $101.87 | 2019-2024 | Xembify |
| Shire North American Group INC | $91.23 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $90.62 | 2025 | Neffy |
| Blueprint Medicines Corporation | $84.16 | 2023-2024 | Ayvakit |
| Sunovion Pharmaceuticals INC. | $75.64 | 2019-2020 | |
| Covis Pharma Gmbh | $72.58 | 2021 | |
| Circassia INC. | $66.17 | 2019-2020 | |
| Phadia US INC. | $53.11 | 2021-2022 | |
| Amarin Pharma, INC. | $51.03 | 2020 | |
| Leo Pharma INC. | $37.62 | 2022-2023 | Adbry |
| Adma Biomanufacturing LLC | $36.75 | 2024 | |
| Organon LLC | $35.03 | 2025 | |
| Optinose US, INC. | $33.73 | 2019-2020 | |
| Hospira, INC. | $31.67 | 2024 | |
| Lilly USA, LLC | $25.38 | 2025 | Ebglyss |
| Abbvie INC. | $21.13 | 2022 | |
| Greer Laboratories, INC. | $20.60 | 2024 | Palforzia |
| Amgen INC. | $15.72 | 2025 | Tezspire |
| Hikma Pharmaceuticals USA | $14.84 | 2023 | Ryaltris |
| Merck Sharp & Dohme LLC | $14.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Frith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.